Stock IMMX IMMIX BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
2.17 USD 0.00% Intraday chart for Immix Biopharma, Inc. +1.88% -68.64%
Apr. 29 Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment MT
Apr. 18 Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
GL
Immix Biopharma on Track to Dose NXC-201 Patients in United States
GL
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy
AQ
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
AQ
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
GL
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
AQ
Immix Biopharma Announces 'Be Proactive in AL' AL Amyloidosis Awareness Initiative
AQ
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
GL
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
AQ
Immix Biopharma 12 Month Review Progress Update
AQ
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
GL
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
AQ
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
GL
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
AQ
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
GL
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
AQ
Immix Biopharma Announces Proposed Public Offering of Common Stock
GL
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
GL
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
AQ
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMMX Stock
  4. News Immix Biopharma, Inc.
  5. Press Releases